Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

AMGEN INC. — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Report

AMGEN INC.

via MICHAEL J. LAMOUREUX

2nd Quarter (Apr 1 - June 30) · 2026Posted Jul 19, 2026Filing document ↗LDA record ↗

Income$10Kfee reported

Client

Name: AMGEN INC.
Description: Biotechnology
Location: District of Columbia · United States of America

Registrant

Firm: MICHAEL J. LAMOUREUX
Location: Russellville, Arkansas, United States of America

Lobbying activities

1 issue

Health Issues
Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests
LobbyistsMICHAEL LAMOUREUX
TargetedSENATE

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.